Cat. No：GM-C34194
Product：H_HER2 HER4 Reporter HEK-293 Cell Line
Cat. No：GM-C34194
Product：H_HER2 HER4 Reporter HEK-293 Cell Line
Cell Growth Medium：DMEM+10% FBS+1% P.S+4 μg/mL Blasticidin+400 μg/mL G418+125 μg/mL Hygromycin+0.75 μg/mL Puromycin
Cell Culture Freezing Medium：90% FBS+10% DMSO
Assay Buffer：DMEM+1% FBS+1% P.S
HER2 (Human Epidermal Growth Factor Receptor 2) and HER4 (Human Epidermal Growth Factor Receptor 4) are both members of the epidermal growth factor receptor family. In cancer research, particularly breast cancer, HER2 has garnered significant attention due to its overexpression in certain tumors.
Overexpression of the HER2 receptor is associated with increased cell proliferation, survival, and invasiveness. HER2-positive breast cancers usually have a poorer prognosis, but targeted therapies against HER2, such as trastuzumab, have markedly improved patient outcomes. HER4 has been studied less extensively in clinical settings. Its role is relatively complex, potentially acting as an anti-tumor factor in some contexts, but it may also promote tumorigenesis in others. Targeting both HER2 and HER4 could help overcome resistance to single-target treatments and improve therapeutic effectiveness. This dual-target approach may be particularly beneficial in tumors expressing both HER2 and HER4.
The H_HER2 HER4 Reporter HEK-293 Cell Line from JimanBio is a luciferase reporter gene cell line, where ligand binding to HER2 and HER4 receptors can activate downstream signaling pathways. This process is followed by measuring luminescence to determine the expression of luciferase, indirectly assessing the ligand's impact on signaling pathways and thus serving to verify the binding effect of the ligand to the receptors.
Cat. No：GM-C34194
Product：H_HER2 HER4 Reporter HEK-293 Cell Line
Cell Growth Medium：DMEM+10% FBS+1% P.S+4 μg/mL Blasticidin+400 μg/mL G418+125 μg/mL Hygromycin+0.75 μg/mL Puromycin
Cell Culture Freezing Medium：90% FBS+10% DMSO
Assay Buffer：DMEM+1% FBS+1% P.S
HER2 (Human Epidermal Growth Factor Receptor 2) and HER4 (Human Epidermal Growth Factor Receptor 4) are both members of the epidermal growth factor receptor family. In cancer research, particularly breast cancer, HER2 has garnered significant attention due to its overexpression in certain tumors.
Overexpression of the HER2 receptor is associated with increased cell proliferation, survival, and invasiveness. HER2-positive breast cancers usually have a poorer prognosis, but targeted therapies against HER2, such as trastuzumab, have markedly improved patient outcomes. HER4 has been studied less extensively in clinical settings. Its role is relatively complex, potentially acting as an anti-tumor factor in some contexts, but it may also promote tumorigenesis in others. Targeting both HER2 and HER4 could help overcome resistance to single-target treatments and improve therapeutic effectiveness. This dual-target approach may be particularly beneficial in tumors expressing both HER2 and HER4.
The H_HER2 HER4 Reporter HEK-293 Cell Line from JimanBio is a luciferase reporter gene cell line, where ligand binding to HER2 and HER4 receptors can activate downstream signaling pathways. This process is followed by measuring luminescence to determine the expression of luciferase, indirectly assessing the ligand's impact on signaling pathways and thus serving to verify the binding effect of the ligand to the receptors.
